Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.

The collaborations will provide Illumina's customers with workflows for genomic disease characterization and spatial mapping.

Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to ...

A new spatial transcriptomic technology captures RNA patterns without requiring expensive imaging ...

"Spatial transcriptomics opens entirely new pathways to gain crucial insight into the cellular function of organisms," said Steve Barnard, PhD, chief technology officer of Illumina. "Illumina spatial ...

Spatial biology first entered the omics scene about a decade ago. Since then, the technology has generated significant buzz both inside and outside of the lab—beyond its contributions to science. The ...

At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands ...